The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsMatthew Kennedy, Mark S. Forman, Larry Ereshefsky et al.|Science Translational Medicine|2016Cited by 416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionMatthew Fell, John A. Morrow, Christian Mirescu et al.|Journal of Pharmacology and Experimental Therapeutics|2015Cited by 336
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D. Scott, Michael W. Miller, John A. McCauley et al.|Journal of Medicinal Chemistry|2017Cited by 147